MONTREAL, July 20, 2021 (GLOBE NEWSWIRE) — Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has received additional funding from RB Capital Partners, Inc. (“RB Capital”) in the amount of $900,000. The investment is in the form of convertible debt with a conversion price set a premium to market of $0.30 per share. This brings the total to just over $3,500,000 that RB Capital has invested in Sunshine Biopharma to date. Sunshine Biopharma will use the proceeds of this new financing to advance the development of the COVID-19 protease inhibitor treatment and Adva-27a, the Company’s flagship anticancer compound.

By A Silva